Development of a New Rapid Diagnostic Test to Support Onchocerciasis Elimination

Status: Recruiting
Location: See location...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Onchocerciasis, also known as river blindness, is one of the disease targeted for elimination by the World Health Organization (WHO) in the group of Neglected Tropical Diseases. Existing diagnostic tools for onchocerciasis have limitations that make mapping, epidemiological assessments and verification of elimination of onchocerciasis difficult. It is in this context that WHO, in its 2021-2030 roadmap for onchocerciasis, has identified the development of new diagnostic tests, or the improvement of existing diagnostic tests, as a critical condition for achieving the goal of eliminating onchocerciasis transmission. To this end, a series of cross-sectional studies will be carried out in Cameroun over a one year period to collect and characterize biological samples for the development and evaluation of a new rapid diagnostic test for onchocerciasis. The study will target individuals aged 18 and over, mono-infected with one of the filarial species Onchocerca volvulus, Loa loa or Mansonella perstans; and non-infected. At the end of this study, data on the endemicity of onchocerciasis, loiasis and mansonellosis in the selected communities will be updated. More importantly, a new rapid diagnostic test will be developed, which can then be used to monitor the activities of onchocerciasis control programs.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:

• Subjects informed of the objectives of the study and who signed a consent form

• Subjects without filariasis (for control subjects), or

• Subjects mono-infected with Onchocerca volvulus, or

• Subjects mono-infected with Loa loa, or

• Subjects mono-infected with Mansonella perstans or alternatively co-infected with Mansonella perstans and Loa loa

Locations
Other Locations
Cameroon
Higher Institute for Scientific and Medical Research
RECRUITING
Yaoundé
Contact Information
Primary
Marie KOENIG
marie.koenig@bioaster.org
+33634452334
Backup
Marion DARNAUD
marion.darnaud@bioaster.org
+33481111002
Time Frame
Start Date: 2024-04-15
Estimated Completion Date: 2025-12
Participants
Target number of participants: 400
Treatments
Other: Group1: Control subjects (non-infected with filariasis)
Blood drawing + feces sample collection
Other: Group 2: Subjects mono-infected with Onchocerca volvulus
Blood drawing + feces sample collection
Other: Group 3: Subjects mono-infected with Loa loa
Blood drawing + feces sample collection
Other: Group 4: Subjects mono-infected with Mansonella perstans (alternatively co-infected with Loa loa)
Blood drawing + feces sample collection
Sponsors
Leads: Bioaster

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

We couldn't find any related articles check for more on the main search page.